Watchlist · 78/100Jul 28, 12:24 PM EDT
Incyte Raises Opzelura Sales Outlook to $1.05B-$1.1B, Lifts 2026 Net Sales Forecast to $5.13B-$5.26B
INCY
Incyte Corporation (INCY) updated its 2026 net sales guidance to $5.130B-$5.260B, driven by an increased Opzelura forecast of $1.050B-$1.1B following a CMS settlement. CEO William Meury highlighted progress in diversifying beyond a single cornerstone product,…
- ▹Opzelura guidance raised to $1.05B-$1.1B after CMS settlement, showing strong commercial demand and regulatory clarity
- ▹Multiple growth drivers beyond cornerstone product, with $5.1B+ revenue forecast indicating diversified pipeline and commercial execution
Watchlist · 70/100Jul 27, 1:44 PM EDT
GSK's Dovato matches Gilead's Biktarvy in head-to-head HIV study
GSKGILD
ViiV Healthcare (majority-owned by GSK) announced that its two-drug HIV regimen Dovato was non-inferior to Gilead's three-drug Biktarvy in a Phase 3b head-to-head trial. The results could bolster Dovato's competitive position against Biktarvy, potentially impa…
- ▹Positive head-to-head data supports Dovato's efficacy vs Biktarvy, strengthening commercial position
- ▹GSK's ViiV has strong HIV franchise with multiple assets and manufacturing partnerships
Neutral · 62/100Jul 28, 10:25 AM EDT
Kiniksa Forecasts $980M-$995M in 2026 Revenue, Pushes KPL-387 into Phase III PASTORALE Trial
KNSA
Kiniksa Pharmaceuticals (KNSA) provided 2026 revenue guidance of $980M-$995M, reflecting strong commercial execution. The company is also advancing KPL-387 into a Phase III trial (PASTORALE), signaling pipeline progress. Investors should note the revenue outlo…
- ▹Strong revenue guidance indicates commercial success for approved products
- ▹Advancing KPL-387 to Phase III adds pipeline value but remains early-stage
Neutral · 58/100Jul 27, 10:28 AM EDT
BioMarin and n-Lorem Join Forces on Antisense Therapy for Rare ReNU Syndrome
BMRNASO
BioMarin (BMRN) is collaborating with the n-Lorem Foundation to develop an antisense oligonucleotide therapy for ReNU syndrome, a rare neurodevelopmental disorder. The partnership leverages BioMarin's expertise in genetic medicines to target the underlying cau…
- ▹Collaboration with n-Lorem Foundation for rare disease ASO therapy; platform potential but early stage.
- ▹Single-asset focus for ultra-rare indication limits commercial upside; no regulatory clarity yet.
Neutral · 55/100Jul 28, 10:06 AM EDT
Corbus Pharma clears FDA hurdle for pivotal ADC trial in oropharyngeal cancer
CRBP
Corbus Pharmaceuticals (CRBP) received FDA clearance to initiate TEMPO-1, a registrational trial for its antibody-drug conjugate CRB-701 in second-line oropharyngeal squamous cell carcinoma. The trial will compare CRB-701 against standard-of-care options, posi…
- ▹FDA greenlight for pivotal trial adds regulatory clarity
- ▹Single-asset micro-cap with no platform or commercial revenue limits upside
Neutral · 55/100Jul 27, 6:23 AM EDT
Legend Biotech CEO Ying Huang Resigns, Board Launches Successor Search
LEGN
Legend Biotech (LEGN) announced that CEO Ying Huang has resigned from both her CEO role and board position, effective July 24, 2026. The board has begun a search for a permanent replacement. This leadership change could impact investor confidence in the compan…
- ▹CEO departure creates leadership uncertainty, but Carvykti is commercialized and partnered with J&J.
- ▹Single-asset risk and leadership gap cap upside; no immediate regulatory or tech catalyst.
Neutral · 50/100Jul 28, 7:29 AM EDT
Altimmune Surges 15%+ as Pemvidutide Shows Promise in Reducing Alcohol Consumption in Phase 2 Trial
ALT
Altimmune (ALT) announced positive topline results from a mid-stage trial of its GLP-1 drug pemvidutide in alcohol use disorder, showing a significant reduction in drinking. Shares jumped over 15% premarket, signaling investor optimism for the drug's potential…
- ▹Positive mid-stage data for GLP-1 in alcohol use disorder, but single-asset risk and early stage limit upside.
- ▹No regulatory clarity or manufacturing details; stock price reaction reflects speculative interest.
Neutral · 50/100Jul 27, 7:18 AM EDT
Precision BioSciences Promotes CFO to COO as Gene-Editing Programs Advance
DTIL
Precision BioSciences (DTIL) announced that CFO Alex Kelly will transition to the newly created COO role, overseeing customer-facing operations. The leadership change comes as the company prepares to advance its lead clinical programs, signaling a strategic fo…
- ▹Management changes signal operational focus but no direct impact on pipeline or regulatory status.
- ▹Single-asset gene editing company with limited near-term catalysts.
High Risk · 47/100Jul 27, 8:40 AM EDT
Sarepta Names Ex-Tessera CEO Michael Severino as New Chief
SRPT
Sarepta Therapeutics (SRPT) appointed Michael Severino as CEO, effective July 28, 2026, succeeding retiring Doug Ingram. Severino, former CEO of Tessera Therapeutics, will also join the board. The leadership change signals a strategic shift as Sarepta advances…
- ▹CEO transition adds uncertainty; no direct impact on pipeline or regulatory status.
High Risk · 42/100Jul 27, 1:57 PM EDT
Sellas Life Sciences Loses Arbitration to 3D Medicines, Ordered to Pay $1M
SLS
3D Medicines won an arbitration against Sellas Life Sciences (SLS), with all of Sellas's claims dismissed. The arbitrator ordered Sellas to reimburse approximately $1.02 million in legal costs, a financial setback for the biotech firm.
- ▹Arbitration win provides minor financial relief but no impact on pipeline or commercial prospects.
- ▹Single-asset micro-cap with no recent positive regulatory or clinical catalysts.
High Risk · 37/100Jul 27, 8:59 AM EDT
Entera Bio Secures $275M in Oversubscribed Private Placement Led by BVF Partners
ENTX
Entera Bio (NASDAQ: ENTX) announced a $275M private placement, oversubscribed and led by existing investor BVF Partners with participation from other healthcare-focused institutional investors. The company will issue 122.96M ordinary shares and 11.84M pre-fund…
- ▹Dilution risk from large placement
- ▹Single-asset micro-cap with no clear catalyst
High Risk · 32/100Jul 28, 8:30 AM EDT
Replimune shares tumble 28% premarket after FDA briefing document raises concerns ahead of RP1 advisory panel
REPLCAPRBMY
Replimune (REPL) shares fell ~28% premarket after the FDA released a briefing document ahead of an advisory committee meeting for its lead drug RP1. The document likely highlighted safety or efficacy concerns, mirroring a similar sell-off in Capricor Therapeut…
- ▹FDA briefing document negative ahead of AdCom, severe regulatory risk
- ▹Single-asset micro-cap with premarket sell-off of ~28%
High Risk · 32/100Jul 27, 7:49 AM EDT
MapLight Therapeutics Plunges 50% as Once-Daily Schizophrenia Drug Misses Key Goal in Phase 2
MPLT
MapLight Therapeutics (MPLT) saw its stock drop 50% premarket after its Phase 2 schizophrenia trial produced mixed results: while the overall study met its primary endpoint, the once-daily dosing regimen failed to achieve statistical significance on that measu…
- ▹Mixed phase 2 data with once-daily dosing failure
- ▹Stock drop of 50% indicates severe market disappointment
High Risk · 22/100Jul 28, 8:20 AM EDT
Enlivex Drops 21% on $400M Token-Linked Stock Offering
ENLV
Enlivex (ENLV) announced a $400M private placement of ordinary shares at $5-$6 per share, with proceeds tied to a treasury strategy using the Rain protocol and RAIN tokens. The dilutive offering sent shares down 21% in pre-market trading to $3.35, signaling in…
- ▹Massive dilution from $400M placement at discount
- ▹Crypto-related treasury strategy adds uncertainty
High Risk · 22/100Jul 27, 10:55 AM EDT
Capricor Shares Tumble 67% After FDA Briefing Raises Doubts on Duchenne Drug
CAPR
Capricor Therapeutics (CAPR) shares plummeted ~67% after an FDA briefing document questioned the efficacy and safety of its Duchenne muscular dystrophy candidate, deramiocel, ahead of a July 29 advisory committee meeting. The negative review raises significant…
- ▹FDA AdCom briefing document questions efficacy and safety, severe regulatory negative
- ▹Single-asset micro-cap with no other pipeline support
High Risk · 0/100Jul 27, 1:52 PM EDT
Polaris Global Equity Composite Shifts Portfolio: New Buys and Sells in Q2
PGVFXADBE
Polaris Global Equity Composite (PGVFX) added new holdings and exited multiple positions in Q2 2026, despite underperforming its benchmark with a 13.26% return versus the MSCI World Index's 13.90%. However, the fund outperformed in the first half of 2026, retu…
- ▹Fund performance news, not biotech-specific
- ▹No relevant biotech information